IP78: Kidney Cancer: Advanced (including drug therapy)
Monday, May 18, 2026 7:00 AM to 9:00 AM · 2 hr. (America/New_York)
147B
Poster and Podium Sessions
Oncology: Kidney
Monday, May 18
IP78-01: Predicting Renal Fossa Recurrence After Radical Nephrectomy for Renal Cell Carcinoma: Surgical Lessons from a 15-Year Update Study
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
IP78-03: Outcomes of nephrectomy in patients with pathologic complete response to immune checkpoint inhibitor therapy for renal cell carcinoma: A multicenter study
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
IP78-04: Cancer-Specific Survival After Synchronous or Metachronous Metastasis Following Surgery for Renal Tumors: A 10-Year Comparative Analysis
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
IP78-05: Does a Fast Growing Tumor Thrombus Portend a Worse Prognosis in Renal Cell Carcinoma?
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
Matthew Mcleay · Mayo Clinic
IP78-06: Response of Venous Tumor Thrombi in Renal Cell Carcinoma to Immune Checkpoint Inhibitor Therapy: A Multicenter Retrospective Cohort Study
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
IP78-07: Comparison between IO–IO and IO–TKI Combination therapies for Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
IP78-08: Impact of Histological Subtype and Metastatic Burden on Overall Survival After Cytoreductive Nephrectomy for Metastatic RCC in the Immunotherapy Era: Insights from the National Cancer Database
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
IP78-09: Impact of cytoreductive nephrectomy and systemic therapy on survival outcomes among metastatic non-clear cell renal cell carcinoma
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
IP78-10: Real-world outcomes of IO-based first-line therapy in metastatic renal cell carcinoma patients on hemodialysis
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
IP78-11: Efficacy of Selective Renal Tumor Embolization Combined with Axitinib and Reduced-Dose Toripalimab in Oligometastatic Clear Cell Renal Carcinoma: An Updated Analysiswith Patient-Derived Organoid and Immune Co-culture Insights.
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
Jun Du
IP78-12: Nivolumab plus Cabozantinib versus Pembrolizumab plus Lenvatinib for Metastatic Renal Cell Carcinoma: A Propensity Score-matched Analysis of Japanese Multicenter Database
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
IP78-13: Beyond Hazard Ratios: A Restricted Mean Survival Time Network Meta-Analysis of First-Line Regimens for Metastatic Clear Cell Renal Cell Carcinoma
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
IP78-14: Application of Restricted Mean Survival Time Analysis to Contemporary Management of Metastatic Renal Rell Carcinoma with Immunotherapy-based Regimens
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
IP78-15: Prognostic impact of early C-reactive protein dynamics in advanced renal cell carcinoma treated with immune checkpoint inhibitor combinations
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
IP78-16: Association of serum kidney injury molecule-1 (KIM-1) with treatment response and survival in metastatic renal cell carcinoma
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
IP78-17: Prior 5-a-Reductase Inhibitor Exposure Associates with Enhanced ICI Benefit in Metastatic RCC: Multicentre Cohort with Single-Cell Immune Profiling
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
IP78-18: ALDOB Regulates the AKT/GLUT1 Axis to Suppress clear cell Renal Cell Carcinoma Progression and Belzutifan Resistance
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
Pengfei Shao
IP78-19: Morphological evolution and immune microenvironment remodeling associated with systemic therapy response are linked to HMGA2 expression in clear cell renal cell carcinoma
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
IP78-20: Who Truly Needs Adjuvant Therapy? A Simple Clinicopathologic Model Identifying Real Candidates for KEYNOTE-564–Defined Intermediate-High–Risk Clear Cell Renal Cell Carcinoma
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
IP78-21: Development and Internal Validation of a Novel Prognostic Score for Real-World Renal Cell Carcinoma Patients Eligible for Adjuvant therapy
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
Rocco Simone Flammia
IP78-22: Real-World Data of Patients Eligible for Adjuvant Pembrolizumab Prior to its National Reimbursement in Italy: Results from an Italian National Cancer Institute Registry
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
Rocco Simone Flammia
IP78-23: Balancing Benefit and Harm – A Multi-Institutional Evaluation of Toxicity and Efficacy of Adjuvant Pembrolizumab for Patients with High-Risk Clear Cell Renal Cell Carcinoma
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
IP78-24: Novel Targeting of the Renal Tumor Microenvironment via Anoikis Induction by DZ-50
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
IP78-25: ADHERENCE TO IMMUNOTHERAPY GUIDELINES FOR METASTATIC KIDNEY CANCER: NATIONAL TRENDS OF ACADEMIC AND COMMUNITY CENTERS
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
IP78-26: Cytoreductive Nephroureterectomy Plus Systemic Therapy versus Systemic Therapy Alone in Metastatic UTUC: An NCDB Propensity-Score Matched analysis
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B
IP78-27: Differential Effects of First-Line IO–TKI and IO–IO Therapy on Muscle and Fat Loss in Metastatic Renal Cell Carcinoma
Monday, May 18, 2026 7:00 AM to 9:00 AM
147B